How dupilumab affects anxiety and depression in moderate-to-severe atopic dermatitis
Observes mood and quality of life in people with atopic dermatitis taking dupilumab.
Plain-language title generated from the registry record
Registry title: The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
Key facts
- Where
- Doha, QatarSee the site
Where in Qatar
- Investigational Site: Hamad Medical CorporationDoha, QatarNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sanofi
- Trial code
- NCT07467564
- Record updated
- 28 July 2026
- Original description
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.Read full original descriptionShow less
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.
Inclusion: Participants who have moderate to severe AD with signs and symptoms of anxiety and/or depression; Participants who initiate dupilumab therapy within 30 days of enrolment, based on the treating physician's decision, independently of study participation; Participants and/or their legally approved representatives (LAR in case of the minor subject) must agree to sign an informed consent or an assent.
Exclusion: Participants with human immunodeficiency virus (HIV), hepatitis B or C, malignancy, or other concomitant illnesses; Participants on antidepressants/anti-anxiety within 6 months of enrolment or those who are planning to receive antidepressants/anti-anxiety. In addition, those who will use antidepressants/anti-anxiety medications throughout the study will be excluded from the analysis; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial; Participants with active chronic or acute infection requiring systemic treatment; Participants who are diagnosed with active endoparasite infection or are suspected of being at high risk of infection; Females who are pregnant, lactating, or planning/intending to be pregnant in the next 6 months; Participants who are participating in another trial.